Literature DB >> 31932680

PHF1 fusions cause distinct gene expression and chromatin accessibility profiles in ossifying fibromyxoid tumors and mesenchymal cells.

Jakob Hofvander1, Vickie Y Jo2, Christopher D M Fletcher2, Florian Puls3, Uta Flucke4, Jenny Nilsson1, Linda Magnusson1, Fredrik Mertens5,6.   

Abstract

Ossifying fibromyxoid tumor (OFMT) is a soft tissue tumor frequently displaying gene fusions, most of which affect the PHF1 gene. PHF1 encodes plant homeodomain finger protein 1, which is involved in various processes regulating gene transcription, including those orchestrated by the polycomb repressor complex 2. Here, a series of 37 OFMTs, including 18 typical, 9 atypical, and 10 malignant variants, was analyzed with regard to transcriptomic features, gene fusion and copy number status, and/or single-nucleotide variants. The effects on gene expression and chromatin accessibility of three detected fusions (EP400-PHF1, MEAF6-PHF1, and PHF1-TFE3) were further evaluated in fibroblasts. Genomic imbalances showed a progression-related pattern, with more extensive copy number changes among atypical/malignant lesions than among typical OFMTs; loss of the RB1 gene was restricted to atypical/malignant OFMTs, occurring in one-third of the cases. RNA sequencing identified fusion transcripts in >80% of the cases analyzed, including a novel CSMD1-MEAF6. The gene-expression profile of OFMT was distinct from that of other soft tissue tumors, with extensive transcriptional upregulation of genes in OFMT. These findings were largely recapitulated in gene fusion-expressing fibroblast lines, suggesting that genes involved in, e.g., Wnt signaling and/or being regulated through trimethylation of lysine 27 in histone 3 (H3K27me3) are pivotal for OFMT development. The genes showing differentially higher expression in fusion-expressing cells paralleled increased chromatin accessibility, as revealed by ATAC sequencing. Thus, the present study suggests that OFMT develops through gene fusions that have extensive epigenetic consequences.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31932680     DOI: 10.1038/s41379-020-0457-8

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  39 in total

1.  Novel recurrent PHF1-TFE3 fusions in ossifying fibromyxoid tumors.

Authors:  Albert J H Suurmeijer; Wangzhao Song; Yun-Shao Sung; Lei Zhang; David Swanson; Christopher D M Fletcher; Brendan C Dickson; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2019-04-17       Impact factor: 5.006

2.  Ossifying fibromyxoid tumor of soft parts. A clinicopathological analysis of 59 cases.

Authors:  F M Enzinger; S W Weiss; C Y Liang
Journal:  Am J Surg Pathol       Date:  1989-10       Impact factor: 6.394

3.  Expanding the molecular signature of ossifying fibromyxoid tumors with two novel gene fusions: CREBBP-BCORL1 and KDM2A-WWTR1.

Authors:  Yu-Chien Kao; Yun-Shao Sung; Lei Zhang; Chun-Liang Chen; Shih-Chiang Huang; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2016-08-26       Impact factor: 5.006

Review 4.  Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes.

Authors:  Fredrik Mertens; Cristina R Antonescu; Felix Mitelman
Journal:  Genes Chromosomes Cancer       Date:  2015-12-18       Impact factor: 5.006

5.  In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets.

Authors:  Elsa Arbajian; Florian Puls; Cristina R Antonescu; Fernanda Amary; Raf Sciot; Maria Debiec-Rychter; Vaiyapuri P Sumathi; Marcus Järås; Linda Magnusson; Jenny Nilsson; Jakob Hofvander; Fredrik Mertens
Journal:  Clin Cancer Res       Date:  2017-09-22       Impact factor: 12.531

6.  Ossifying fibromyxoid tumor of soft parts: a clinicopathologic, proteomic, and genomic study.

Authors:  Rondell P D Graham; Sarah Dry; Xinmin Li; Scott Binder; Armita Bahrami; Susana C Raimondi; Ahmet Dogan; Subhankar Chakraborty; Joshua J Souchek; Andrew L Folpe
Journal:  Am J Surg Pathol       Date:  2011-11       Impact factor: 6.394

7.  Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma.

Authors:  Cristina R Antonescu; Yun-Shao Sung; Chun-Liang Chen; Lei Zhang; Hsiao-Wei Chen; Samuel Singer; Narasimhan P Agaram; Andrea Sboner; Christopher D Fletcher
Journal:  Genes Chromosomes Cancer       Date:  2013-11-28       Impact factor: 5.006

8.  Ossifying fibromyxoid tumor of soft parts--a clinicopathologic and immunohistochemical study of 104 cases with long-term follow-up and a critical review of the literature.

Authors:  Markku Miettinen; Val Finnell; John F Fetsch
Journal:  Am J Surg Pathol       Date:  2008-07       Impact factor: 6.394

Review 9.  Ossifying fibromyxoid tumor of soft parts: a clinicopathologic study of 70 cases with emphasis on atypical and malignant variants.

Authors:  Andrew L Folpe; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2003-04       Impact factor: 6.394

10.  Recurrent rearrangement of the PHF1 gene in ossifying fibromyxoid tumors.

Authors:  Samuel Gebre-Medhin; Karolin H Nord; Emely Möller; Nils Mandahl; Linda Magnusson; Jenny Nilsson; Vickie Y Jo; Fredrik Vult von Steyern; Otte Brosjö; Olle Larsson; Henryk A Domanski; Raf Sciot; Maria Debiec-Rychter; Christopher D M Fletcher; Fredrik Mertens
Journal:  Am J Pathol       Date:  2012-07-13       Impact factor: 4.307

View more
  4 in total

1.  Absence of TFE3 Immunoexpression in a Spectrum of Cutaneous Mixed Tumors: A Retrospective Pilot Study.

Authors:  Hatice B Zengin; Bahadir Yildiz; Tatsiana Pukhalskaya; Bruce R Smoller
Journal:  Dermatopathology (Basel)       Date:  2022-01-29

2.  Fully exploiting SNP arrays: a systematic review on the tools to extract underlying genomic structure.

Authors:  Laura Balagué-Dobón; Alejandro Cáceres; Juan R González
Journal:  Brief Bioinform       Date:  2022-03-10       Impact factor: 11.622

3.  Down-regulated m6A reader FTO destabilizes PHF1 that triggers enhanced stemness capacity and tumor progression in lung adenocarcinoma.

Authors:  Jinfeng Ning; Fengjiao Wang; Jianlong Bu; Kaibin Zhu; Wei Liu
Journal:  Cell Death Discov       Date:  2022-08-09

Review 4.  Critical Roles of Polycomb Repressive Complexes in Transcription and Cancer.

Authors:  Guan-Jun Dong; Jia-Le Xu; Yu-Ruo Qi; Zi-Qiao Yuan; Wen Zhao
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.